Regeneron’s Post

R&D is often the single most expensive stage of bringing a new medicine to market. But by creating a valuable investment incentive, M&A helps the life science ecosystem mitigate these costs by attracting much-needed funding for costly and long-running clinical trials, providing resources to begin manufacturing at scale and more necessary to bring a new medicine to market. Read the rest of the breakdown here: https://lnkd.in/ecQ3a7Ng

In the ever-evolving landscape of medical science, developing new drugs and therapies is a process fraught with complexities, rigorous testing, and stringent regulations. In our latest blog will explore the Fast Track program, how it works, and its significant impact on bringing innovative treatments to those in need. Learn more here: https://lnkd.in/gMqVd52B

Only 3 days to go until BIO-Europe Spring! Stay tuned to our LinkedIn page where we will be sharing daily highlights throughout the conference. If you are attending, book a meeting with one of our solution experts to learn more about how Diaceutics are uniquely positioned to help you achieve commercialization success for your precision medicine. Book a meeting here: https://lnkd.in/ehbKKaPn #BIOEuropeSpring #PrecisionMedicine  

With 750+ studies, 19+ human clinical trials, countless testimonials and continued research – we'd argue that yes, MitoQ really does work 🙌⁠ ⁠ But it depends on what you’re hoping MitoQ will do for you.⁠ ⁠ Learn more about MitoQ research here: https://bit.ly/3PDQ4uX

Clinical trials remain a costly and time-consuming process due to age-old industry challenges like recruitment and supply chain optimization, as well as those stemming from new medical innovations, competition from emerging players, and an exponential increase in data. In our most recent POV 👇 https://bit.ly/4aXOvSl David Ghesquieres explores how life sciences organizations can leverage powerful new digital and data capabilities and new trial designs to increase program efficiency, speed, and access.

Get four key insights on increasing diversity in clinical research and advancing clinical trials in Latin America. Read our blog.

Get four key insights on increasing diversity in clinical research and advancing clinical trials in Latin America. Read our blog.

Today is #InternationalClinicalTrialsDay! As Sponsor of innovative clinical trials, GCAR is dedicated to the advancement of science by modernizing clinical trials to accelerate the time from discovery in the lab to use in the clinic resulting in better treatments and lives saved. To learn more about our research, visit: gcaresearch.org #clinicalresearch #clinicaltrials #masterprotocol #platformtrial

How can we unlock the potential of digitizing clinical trials, accelerating research and improving the experience for patients and sites? In collaboration with Transcelerate, my colleague Kelsey Jakee sheds light on the incremental steps companies can take to bring about positive change #ClinicalTrials #DigitalTransformation #PharmaInnovation

How can decentralized clinical trial models and innovative approaches cultivate opportunities for a sustainable future in clinical research? Our expert Michael J Cohen, MSc, MBA explains more. » https://bit.ly/3RnWHlY #sustainability #clinicaltrials #clinicalresearch #drugdevelopment